ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

NIH Says Its Probe Found Charges Of Double Payment “Basically Correct”

October 23, 1981

FA Drug Approval on Activity, Rather Than Survival Urged By NCU

January 13, 1989

IMRT Usage and Cost Related to Geography And Medicare Reimbursement Policy, Study Finds

April 29, 2011

Schmidt Already Working For NIH Despite His Opposition To Kennedy’s New Research Panel

April 5, 1974

Upton Closer To Decision On Control, Centers Merger; ACCC Defeats Motion In Opposition

March 16, 1979

Extramural Advisory Board Members Listed

October 20, 1995